Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a combination of two antibiotics, ceftriaxone and cloxacillin, used together to treat bacterial infections. Ceftriaxone is a third-generation cephalosporin antibiotic with broad-spectrum activity against gram-negative and some gram-positive bacteria. It works by inhibiting bacterial cell wall synthesis, leading to cell death. Cloxacillin is a beta-lactamase-resistant penicillin antibiotic effective primarily against penicillinase-producing staphylococci; it also inhibits bacterial cell wall synthesis. The combination leverages the broad coverage of ceftriaxone with the staphylococcal coverage of cloxacillin, making it useful for mixed infections or empirical therapy where both types of bacteria are suspected.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ceftriaxone + cloxacillin.